Volume 32, No 9, Sep 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 9, September 2022: 862-865

LETTERS TO THE EDITOR

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding

Yingdan Wang^1,† , Wuqiang Zhan^1,† , Jiangyan Liu^1,2,† , Yanqun Wang^3,† , Xiang Zhang¹ , Meng Zhang¹ , Lin Han¹ , Yunping Ma¹ , Lu Lu¹ , Yumei Wen¹ , Zhenguo Chen¹ , Jincun Zhao^3,4,* , Fan Wu^2,* , Lei Sun^1,* , Jinghe Huang^1,*

¹Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Fifth People’s Hospital, Shanghai Public Health Clinical Center, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai, China
²Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China
³State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
⁴Institute of Infectious Disease, Guangzhou Eighth People’s Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
^†These authors contributed equally: Yingdan Wang, Wuqiang Zhan, Jiangyan Liu, Yanqun Wang
Correspondence: Jincun Zhao(zhaojincun@gird.cn)Fan Wu(wufan@fudan.edu.cn)Lei Sun(llsun@fudan.edu.cn)Jinghe Huang(Jinghehuang@fudan.edu.cn)

Dear Editor,

The constant evolution of SARS-CoV-2 has resulted in the emergence of circulating variants during the COVID-19 pandemic. Recently, a newly emerged B.1.1.529 (Omicron) variant raised global concern. Compared with the original SARS-CoV-2 strain and other variants of concern (VOCs), the Omicron variant has more than 30 mutations on its spike (S) protein,1 of which 16 mutations are located in the receptor-binding domain (RBD). These mutations confer significant resistance to neutralizing antibodies elicited by COVID-19 convalescents2,3 or individuals who have received mRNA vaccines4,5 or inactivated vaccines.6 A recent study indicated that most SARS-CoV-2-specific monoclonal antibodies, including FDA-approved antibodies, have lost efficacy against the Omicron variant.7 The Omicron variant has become the dominant strain worldwide, making it urgent to update the vaccination strategy or develop new antibodies to catch up with the pandemic.

https://doi.org/10.1038/s41422-022-00684-0

FULL TEXT | PDF

Browse 666